title: Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers.
abstract: BACKGROUND
  The therapeutic effect of drugs inhibiting acid production on acid-related discomforts is related to both the onset and duration of action of the drug. The effects on gastric pH by single oral doses of some acid-inhibiting drugs were investigated by measuring daytime (morning to lunch) intragastric pH in healthy volunteers.
  
  
  METHODS
  This randomized, single-dose, 4-way crossover study included 15 healthy fasting subjects. Effervescent ranitidine tablets 150 and 300 mg, fast-dissolving famotidine tablets 20 mg and capsules of omeprazole 20 mg were administered. Measurements of intragastric pH were performed every 4 s for 10 min prior to drug administration and during the following 4 h.
  
  
  RESULTS
  The effervescent ranitidine tablets (150 or 300 mg) produced similar changes in intragastric pH: following an immediate increase to about pH 5, intragastric pH decreased slightly over the next 10-20 min. Thereafter pH increased steadily, reaching pH 4 after 20-40 min and pH 6 after about 70 min. After famotidine, pH 4 was reached after 80 min, significantly slower than ranitidine. After omeprazole, pH 3 was never reached. Ranitidine 150 and 300 mg showed significantly larger integrated pH responses over the 4-h observation period, compared to famotidine (P = 0.0288 and 0.0074) or omeprazole (P < 0.001).
  
  
  CONCLUSIONS
  After single-dose administration to healthy fasting volunteers), ranitidine effervescent tablets showed a significantly more rapid onset of action and a significantly larger integrated pH response compared to either famotidine 20 mg fast-dissolving tablets or omeprazole 20 mg capsules.
authors.affiliation: Department of Clinical Physiology, University Hospital, Uppsala, Sweden.
authors.forename: H
authors.initials: H
authors.lastname: Hedenström
authors.forename: C
authors.initials: C
authors.lastname: Alm
authors.forename: M
authors.initials: M
authors.lastname: Kraft
authors.forename: A
authors.initials: A
authors.lastname: Grahnén
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002214:Capsules; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D015738:Famotidine / Q000627:therapeutic use; D005215:Fasting; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D012995:Solubility; D013607:Tablets; D013997:Time Factors
chemical_list: D000897:Anti-Ulcer Agents; D002214:Capsules; D013607:Tablets; D015738:Famotidine; D011899:Ranitidine; D009853:Omeprazole